sapt – Übersetzung – Keybot-Wörterbuch

Spacer TTN Translation Network TTN TTN Login Français English Spacer Help
Ausgangssprachen Zielsprachen
Keybot 43 Ergebnisse  www.hc-sc.gc.ca
  Mot d'ouverture de la S...  
Stratégie d'accès aux produits thérapeutique (SAPT) - mise en oeuvre des initiatives du programme de SAPT - le cabinet et le conseil du trésor ont approuvé une stratégie afin de tenir les engagements du discours du trône et du budget de 2003;
Therapeutic Access Strategy - Implementation of TAS Program Initiatives - Cabinet and Treasury Board has approved a strategy for delivering on the Speech from the Throne and Budget 2003 commitments;
  Ébauche résumé de l'ana...  
La Direction générale des produits de santé et des aliments instituait alors une Stratégie d'accès aux produits thérapeutiques (SAPT) afin d'établir un plan cohérent dans toute la Direction générale pour améliorer certains aspects, y compris la transparence.
is silent on the management of information received or generated by Health Canada. During the public national consultation on health protection legislative renewal, it was made clear by interested parties that government actions should be more transparent. The report of the committee of the Science Advisory Board which looked into the issue of the Drug Review Process indicated that new standards of access to information at all stages of the drug review process are necessary to enhance transparency and public confidence. The Health Products and Food Branch instituted a Therapeutic Access Strategy (TAS) in order to establish a coherent plan throughout the Branch to make improvements in areas including transparency. Efforts previously identified to enhance transparency in the drug review process, including the Summary Basis of Decision initiative, were brought under the TAS umbrella to coordinate and fund all inter-related activities appropriately.
  Annonce : Dr Pierre Cha...  
Le Dr Pierre Charest a prêté son concours à des priorités importantes de Santé Canada ayant trait à la Stratégie d'accès aux produits thérapeutiques (SAPT), à l'innocuité des médicaments ainsi qu'aux cellules, tissus et organes.
Since joining the federal public service in 1989, Dr. Pierre Charest has held several senior level management positions within the Canadian Forest Service and Natural Resources Canada. More recently, within the Health Products and Food Branch, Dr. Charest was the Director General of the Office of Biotechnology and Science, and the Acting Director General of the Biologics and Genetic Therapies Directorate. Dr. Charest has contributed to major Health Canada priorities on the Therapeutic Access Strategy, Drug Safety, and Cells, Tissues and Organs. A prolific author and researcher, Dr. Charest has written or co-written 75 scientific publications, written or directed 20 internal reports for Health Canada and the Canadian Forest Service on biotechnology and on the management of science and technology, presented 80 scientific communications and delivered 30 invited lectures. He holds a Doctorate Degree in Molecular Biology from Carleton University, and Masters and Bachelor Degrees in Agronomy from Laval University. Dr. Charest's office is located in Ottawa and he can be reached at 613-957-8065 or by email at pierre_charest@hc-sc.gc.ca.
  Ébauche résumé de l'ana...  
Afin de réduire les répercussions globales au moment du déploiement initial, une approche progressive a été proposée (se reporter à la Section 5B). De plus, l'utilisation de rédacteurs techniques pour rédiger les documents a été proposée et appuyée grâce à des fonds de la SAPT.
It is anticipated that the impact on TPD and BGTD workload, as a result of SBD implementation, should be manageable. Upfront effort on the part of reviewers and regulatory project managers in the training of scientific writers and more so the vetting of documents is expected to result in a relatively seamless transition. In an attempt to reduce the overall impact at the time of initial rollout, a phased approach has been proposed (refer to Section 5B). In addition, the use of technical writers to complete the documents has been proposed and has been supported through funding from TAS. Specifically, technical writers shall complete the documents, with reviewers vetting for accuracy and integrity. The scientific writers will ensure the documents are written with a clarity and tone suitable for the intended audience and introduce consistency into the creation, style and wording of the documents. Review staff will be tasked with responding to scientific writer's questions and concerns in a timely manner. Scientific writers would ensure timely completion of the SBDs such that questions can be relayed to review staff while the information is still current in their minds.
  MedEffet Canada - Au su...  
MedEffet est un des produits de la Stratégie d'accès aux produits thérapeutiques (SAPT). La SAPT est un plan quinquennal visant à améliorer la sécurité et l'efficacité des produits thérapeutiques, et à les rendre plus accessibles aux Canadiens et Canadiennes.
MedEffect is one of the deliverables of the Therapeutic Access Strategy (TAS), a five-year strategy to improve the safety, effectiveness and access to therapeutic products available to Canadians. The MedEffect program will be comprised of a website, and a partnership initiative involving, for example, professional health care associations and consumer/patient groups. Partnering with outside associations and groups will help to expand and maintain the community of networks knowledgeable about MedEffect. Through these networks, it is hoped new opportunities will arise to share information more effectively by creating links between MedEffect and the websites or publications of the participating partners.
  Au service des Canadien...  
Le Plan stratégique de la DGPSA englobe les objectifs de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada. La SAPT rassemble les idées les plus créatrices au sein et à l'extérieur du gouvernement en vue de transformer l'approche de Santé Canada en matière de réglementation des produits de santé et donner aux Canadiens un meilleur accès à ces produits.
The HPFB Strategic Plan encompasses the objectives of Health Canada's Therapeutics Access Strategy (TAS). TAS brings together the most creative thinking inside and outside government to transform Health Canada's approach to the regulation of health products and improve Canadians' access to those products. The overarching objective of TAS is to improve the health of Canadians through enhanced access to safe, effective, appropriately used, and affordable therapies. The strategy is a comprehensive set of linked measures dealing with innovation, modernization of regulatory regimes, and a strengthened focus on real world safety, therapeutic effectiveness and sustainable access to therapeutic products.
  Au service des Canadien...  
Par l'entremise de la Stratégie d'accès aux produits thérapeutiques (SAPT), la Direction générale améliorera la rapidité, la transparence et l'aspect prévisible de ses processus réglementaires pour les évaluations pré-commercialisation des produits de santé et des aliments, fera une analyse comparative de ces derniers en tenant compte des principales pratiques internationales, tout en maintenant les normes élevées de sécurité de Santé Canada.
Through expanded collaboration with its international partners, the Branch will leverage expertise and knowledge and ensure the application of sound regulatory practices and standards that are consistent, whenever possible, with leading international standards and norms. The Branch will also increase information-sharing and joint activities with international regulators to support more efficient and effective regulatory decision-making and enable quicker identification of risks associated with health products and food available in the market.
  Ébauche résumé de l'ana...  
Les présentations ont été livrées au comité directeur de la SAPT et des consultations seront créées conjointement avec des intrants provenant du Bureau de la consommation et de la participation du public (BCPP) afin de fournir une représentation adéquate et appropriée aux prochains lieux de réunion.
Linkages with other HPFB directorates have been identified and steps taken to ensure that viewpoints are received and addressed accordingly. Representation on the working group includes membership from TPD, BGTD and MHPD. VDD and NHPD have been contacted with offers to deliver presentations and solicit working group participation should they feel this is necessary. Presentations have been delivered to the TAS Steering Committee and consultations will be developed in conjunction with input from the Office of Consumer Affairs and Public Involvement to ensure adequate and appropriate representation at forthcoming venues.
  Au service des Canadien...  
Le Plan stratégique de la DGPSA englobe les objectifs de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada. La SAPT rassemble les idées les plus créatrices au sein et à l'extérieur du gouvernement en vue de transformer l'approche de Santé Canada en matière de réglementation des produits de santé et donner aux Canadiens un meilleur accès à ces produits.
The HPFB Strategic Plan encompasses the objectives of Health Canada's Therapeutics Access Strategy (TAS). TAS brings together the most creative thinking inside and outside government to transform Health Canada's approach to the regulation of health products and improve Canadians' access to those products. The overarching objective of TAS is to improve the health of Canadians through enhanced access to safe, effective, appropriately used, and affordable therapies. The strategy is a comprehensive set of linked measures dealing with innovation, modernization of regulatory regimes, and a strengthened focus on real world safety, therapeutic effectiveness and sustainable access to therapeutic products.
  Rapport sommaire des in...  
Santé Canada a élaboré la Stratégie d'accès aux produits thérapeutiques (SAPT), avec des partenaires et des intervenants, afin d'aider les Canadiens et Canadiennes à maintenir et à améliorer leur état de santé, et de donner suite aux engagements pris.
The inspections were conducted in accordance with procedures and guidance documents developed by the Inspectorate for PMRC inspections. The "Inspection Strategy for Post-Market Reporting Compliance (POL-0041)" provides further guidance for the effective and uniform conduct of these inspections. The "Risk Classification of Post-Market Reporting Compliance Observations" is a guide to classify the observations noted during PMRC inspections to their risk. Furthermore, the Marketed Health Products Directorate "Guidance Document for Industry - Reporting Adverse Drug Reactions to Marketed Health Products"5 provides guidance to industry on reporting adverse reactions to marketed drugs.
  Au service des Canadien...  
Le Plan stratégique de la DGPSA englobe les objectifs de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada. La SAPT rassemble les idées les plus créatrices au sein et à l'extérieur du gouvernement en vue de transformer l'approche de Santé Canada en matière de réglementation des produits de santé et donner aux Canadiens un meilleur accès à ces produits.
The HPFB Strategic Plan encompasses the objectives of Health Canada's Therapeutics Access Strategy (TAS). TAS brings together the most creative thinking inside and outside government to transform Health Canada's approach to the regulation of health products and improve Canadians' access to those products. The overarching objective of TAS is to improve the health of Canadians through enhanced access to safe, effective, appropriately used, and affordable therapies. The strategy is a comprehensive set of linked measures dealing with innovation, modernization of regulatory regimes, and a strengthened focus on real world safety, therapeutic effectiveness and sustainable access to therapeutic products.
  MedEffet Canada - Au su...  
MedEffet est un des produits de la Stratégie d'accès aux produits thérapeutiques (SAPT). La SAPT est un plan quinquennal visant à améliorer la sécurité et l'efficacité des produits thérapeutiques, et à les rendre plus accessibles aux Canadiens et Canadiennes.
MedEffect is one of the deliverables of the Therapeutic Access Strategy (TAS), a five-year strategy to improve the safety, effectiveness and access to therapeutic products available to Canadians. The MedEffect program will be comprised of a website, and a partnership initiative involving, for example, professional health care associations and consumer/patient groups. Partnering with outside associations and groups will help to expand and maintain the community of networks knowledgeable about MedEffect. Through these networks, it is hoped new opportunities will arise to share information more effectively by creating links between MedEffect and the websites or publications of the participating partners.
  Rapport sommaire des in...  
Santé Canada a élaboré la Stratégie d'accès aux produits thérapeutiques (SAPT), avec des partenaires et des intervenants, afin d'aider les Canadiens et Canadiennes à maintenir et à améliorer leur état de santé, et de donner suite aux engagements pris.
The inspections were conducted in accordance with procedures and guidance documents developed by the Inspectorate for PMRC inspections. The "Inspection Strategy for Post-Market Reporting Compliance (POL-0041)" provides further guidance for the effective and uniform conduct of these inspections. The "Risk Classification of Post-Market Reporting Compliance Observations" is a guide to classify the observations noted during PMRC inspections to their risk. Furthermore, the Marketed Health Products Directorate "Guidance Document for Industry - Reporting Adverse Drug Reactions to Marketed Health Products"5 provides guidance to industry on reporting adverse reactions to marketed drugs.
  MedEffet - Centre de re...  
Santé Canada a élaboré la Stratégie d'accès aux produits thérapeutiques (SAPT), avec des partenaires et des intervenants, afin d'aider les Canadiens et Canadiennes à maintenir et à améliorer leur état de santé, et de donner suite aux engagements pris.
Health Canada developed the Therapeutics Access Strategy (TAS), with partners and stakeholders, to help Canadians maintain and improve their health, and to respond to these commitments. TAS supports Health Canada's efforts to ensure that human drugs and other therapeutic products are as safe as possible, accessible, of high quality, therapeutically effective, and used properly.
  Rapport sommaire des in...  
Santé Canada a élaboré la Stratégie d'accès aux produits thérapeutiques (SAPT), avec des partenaires et des intervenants, afin d'aider les Canadiens et Canadiennes à maintenir et à améliorer leur état de santé, et de donner suite aux engagements pris.
The inspections were conducted in accordance with procedures and guidance documents developed by the Inspectorate for PMRC inspections. The "Inspection Strategy for Post-Market Reporting Compliance (POL-0041)" provides further guidance for the effective and uniform conduct of these inspections. The "Risk Classification of Post-Market Reporting Compliance Observations" is a guide to classify the observations noted during PMRC inspections to their risk. Furthermore, the Marketed Health Products Directorate "Guidance Document for Industry - Reporting Adverse Drug Reactions to Marketed Health Products"5 provides guidance to industry on reporting adverse reactions to marketed drugs.
  Ébauche résumé de l'ana...  
La charge de travail exigée à la suite d'une mise en oeuvre immédiate et complète (c'est-à-dire la création d'un SMD pour tous les types de présentations mentionnées ci-dessus) serait très lourde sur les deux directions et aurait un effet négatif sur la charge de travail actuelle des examens, la dernière n'étant pas une option acceptable en raison des engagements sous la stratégie d'accès aux produits thérapeutiques (SAPT).
, exclusion of NCs is recommended due to the high volume received annually and consequently the significant additional burden their inclusion would pose on resources. In addition, NCs are frequently filed in relation to changes in chemistry and manufacturing data, most of which is considered confidential under current interpretations and would therefore be excluded from inclusion in the SBD. Disclosable information pertaining to such changes will often be reflected in amendments to the approved PM and as such, would become available at a later date.
  MedEffet Canada - Foir...  
MedEffet Canada est une initiative qui fait partie de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada, une stratégie quinquennale visant à améliorer la sécurité et l'efficacité des produits thérapeutiques offerts aux Canadiennes et aux Canadiens, ainsi que l'accès à ceux-ci.
MedEffect Canada's is one initiative that's part of Health Canada's Therapeutic Access Strategy (TAS), a five-year strategy to improve the safety, effectiveness and access to therapeutic products available to Canadians. MedEffect Canada's goal is to provide centralized access to new safety information about marketed health products in an easy to find, easy to remember location, on the new Health Canada Internet.
  Ébauche résumé de l'ana...  
L'introduction de l'initiative de stratégie d'accès aux produits thérapeutiques (SAPT) au sein de la Direction générale des produits de santé et des aliments (DGPSA) de Santé Canada vient répondre aux messages transmis dans le discours du Trône (2002).
The Therapeutic Access Strategy (TAS) initiative was launched within the Health Products and Food Branch (HPFB) of Health Canada in direct response to messages conveyed in the Speech from the Throne (2002). The TAS framework sets out the objective for HPFB to operate as a timely, transparent, innovative and sustainable regulator. The SBD initiative represents a key deliverable under the transparency agenda of TAS while aligning Health Canada with efforts in foreign jurisdictions.
  Ébauche résumé de l'ana...  
L'introduction de l'initiative de stratégie d'accès aux produits thérapeutiques (SAPT) au sein de la Direction générale des produits de santé et des aliments (DGPSA) de Santé Canada vient répondre aux messages transmis dans le discours du Trône (2002).
The Therapeutic Access Strategy (TAS) initiative was launched within the Health Products and Food Branch (HPFB) of Health Canada in direct response to messages conveyed in the Speech from the Throne (2002). The TAS framework sets out the objective for HPFB to operate as a timely, transparent, innovative and sustainable regulator. The SBD initiative represents a key deliverable under the transparency agenda of TAS while aligning Health Canada with efforts in foreign jurisdictions.
  Ébauche résumé de l'ana...  
L'introduction de l'initiative de stratégie d'accès aux produits thérapeutiques (SAPT) au sein de la Direction générale des produits de santé et des aliments (DGPSA) de Santé Canada vient répondre aux messages transmis dans le discours du Trône (2002).
The Therapeutic Access Strategy (TAS) initiative was launched within the Health Products and Food Branch (HPFB) of Health Canada in direct response to messages conveyed in the Speech from the Throne (2002). The TAS framework sets out the objective for HPFB to operate as a timely, transparent, innovative and sustainable regulator. The SBD initiative represents a key deliverable under the transparency agenda of TAS while aligning Health Canada with efforts in foreign jurisdictions.
  MedEffet - Centre de re...  
Santé Canada a élaboré la Stratégie d'accès aux produits thérapeutiques (SAPT), avec des partenaires et des intervenants, afin d'aider les Canadiens et Canadiennes à maintenir et à améliorer leur état de santé, et de donner suite aux engagements pris.
Health Canada developed the Therapeutics Access Strategy (TAS), with partners and stakeholders, to help Canadians maintain and improve their health, and to respond to these commitments. TAS supports Health Canada's efforts to ensure that human drugs and other therapeutic products are as safe as possible, accessible, of high quality, therapeutically effective, and used properly.
  Ébauche résumé de l'ana...  
23. Persuader les centres de responsabilité de participation du public de la DGPSA, notamment le Bureau de la participation des consommateurs et du public (BPCP) et le sous-comité SAPT de participation des consommateurs et du public, de s'assurer d'avoir ou de rechercher une représentation appropriée pour les consultations de RMD.
Engage HPFB public involvement responsibility centres, including the Office of Consumer and Public Involvement (OCAPI) and the public and consumer involvement TAS sub-committee, on ensuring appropriate representation is achieved and/or sought for SBD consultations.
  L'accès aux produits th...  
En réponse à ses engagements, Santé Canada a élaboré plusieurs initiatives, notamment la Stratégie d'accès aux produits thérapeutiques (SAPT), la Stratégie nationale sur les produits pharmaceutiques et de nouveaux outils visant à améliorer la sûreté et la transparence du système de réglementation des produits thérapeutiques.
Health Canada has several initiatives underway in response to these commitments, including the Therapeutics Access Strategy (TAS), the National Pharmaceuticals Strategy and new tools to improve the safety and transparency of the regulatory system for therapeutic products.
  Ébauche résumé de l'ana...  
Recommandation : Engager des centres de responsabilités de participation du public de la DGPSA, notamment le Bureau de la consommation et de la participation du public (BCPP) et le sous-comité de la SAPT pour la participation du consommateur et du public, et s'assurer de chercher et d'accomplir un représentation appropriée pour les consultations des SMD.
Recommendation: Engage HPFB public involvement responsibility centres, including the Office of Consumer and Public Involvement (OCAPI) and the public and consumer involvement TAS sub-committee, on ensuring appropriate representation is sought and achieved for SBD consultations.
  L'accès aux produits th...  
La SAPT a reçu 190 millions de dollars sur cinq ans dans le budget fédéral de 2003. Pour un bilan, veuillez consulter
TAS received $190 million over five years from the 2003 federal budget. For information on progress, refer to
  Initiative de l'amélior...  
L'Initiative d'amélioration de la capacité d'examen, un élément de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada et de la Stratégie de transformation des activités de la DPT, vise à améliorer la capacité de la DPT, formuler des décisions de qualité en temps opportun sur les produits pharmaceutiques et les matériels médicaux à usage humain.
The Enhanced Review Capacity Initiative, a component of Health Canada's Therapeutic Access Strategy (TAS) and TPD's Business Transformation Strategy, is designed to increase TPD's capacity to deliver quality, timely decisions on pharmaceuticals and medical devices for human use. The initiative will build TPD's internal scientific capacity, increase corporate flexibility to meet performance targets, support long-term human resources planning and training, and provide an enhanced ability to draw on external scientific expertise.
  La gestion de project d...  
Dans le cadre de l'initiative de transformation opérationnelle de la Stratégie d'accès aux produits thérapeutiques (SAPT), la Direction des produits biologiques et des thérapies génétiques (DPBTG) a adopté l'approche de gestion de projet pour améliorer ses pratiques actuelles de gestion des présentations.
As an element of the Therapeutic Access Strategy (TAS) initiative on business transformation, a project management approach has been adopted to the review process in the Biologics and Genetic Therapies Directorate (BGTD) in order to strengthen current review management practices. It is expected that increased efficiencies will be achieved through improved communication within the teams, setting of associated achievable milestones, pro-active troubleshooting and problem-solving, co-ordination of the review process and progress monitoring.
  La gestion de project d...  
La gestion de projet tirera des éléments d'autres initiatives en cours à la SAPT, comme les activités menées avec la Direction générale des produits de santé et des aliments et qui ont trait aux bonnes pratiques d'examen et aux bonnes d'orientation, au règlement extrajudiciare des différends et à la coopération internationale en matière de réglementation.
The project management approach will draw from other TAS initiatives such as Good Review and Good Guidance Practices, Alternate Dispute Resolution and International Regulatory Cooperation activities undertaken within Health Products and Food Branch.
  Mot d'ouverture de la S...  
Stratégie d'accès aux produits thérapeutique (SAPT) - mise en oeuvre des initiatives du programme de SAPT - le cabinet et le conseil du trésor ont approuvé une stratégie afin de tenir les engagements du discours du trône et du budget de 2003;
Therapeutic Access Strategy - Implementation of TAS Program Initiatives - Cabinet and Treasury Board has approved a strategy for delivering on the Speech from the Throne and Budget 2003 commitments;
  Foire aux questions  
R : L'IACE est une composante de la Stratégie d'accès aux produits thérapeutiques (SAPT) de Santé Canada et de la Stratégie de transformation opérationnelle de la Direction des produits thérapeutiques (DPT).
A: ERCI is a component of Health Canada's Therapeutic Access Strategy (TAS) and the Therapeutic Product Directorate's (TPD) Business Transformation Strategy. This initiative involves building internal scientific capacity as well as the appropriate use of expert advice from external sources such as drug or disease experts, professional associations, scientific advisory panels or academic institutions.
1 2 Arrow